Burkitt Lymphoma
Conditions
Brief summary
This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.
Detailed description
This is the 4th Burkitt's Lymphoma (LMB) study by the GFAOP group. This study hopes to include at least 14 Sub Saharian countries some of whom have never participated in a LMB study. The evaluation of improvement in early diagnosis should be possible in this study. The study hopes to be able to evaluate children earlier, with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for children with a stage IV disease. Starting from 2026 we now have the possibility of introducing rituximab into the treatment of African children with Burkitt lymphoma, starting from 15/03/2026. This amendment will prospectively evaluate the toxicity and effectiveness of adding rituximab to the current therapeutic recommendations. These results will be compared with those observed during the first years of implementation in two GFAOP units: specifically, the unit at CHU Yalgado Ouagadougou in Burkina Faso and CHU Treichville in Abidjan, Ivory Coast.
Interventions
OTHEROBSERVATIONAL
OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE
Sponsors
French Africa Pediatric Oncology Group
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Inclusion criteria
Clinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment. \-
Exclusion criteria
Not a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the number of cases with local disease. | 5 years | evaluating the initial clinical reports and later histological reports to confirm the diagnosis and the stage. |
| Evaluation of the number of cases by stage at the time of diagnosis. | 5 Years | evaluating the initial clinical reports and later histological reports to confirm the stage and the diagnosis. |
| Evaluating the treatment given. | 5 Years | Comparison of treatment given and recommended treatment. |
| Evaluating the follow up after treatment. | 5 Years | How many children alive or dead after treatment |
| Number of relapse cases | 5 years | The evaluation and the treatment of relapse and outcome |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Application of therapeutic recommendations | 5 years | Evaluations of the correct application of recommendations |
Countries
Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo, Madagascar, Mali, Senegal
Contacts
CONTACTChantal Ms BOUDA, Dr.
CONTACTBRENDA MALLON, MSc PhD
Outcome results
None listed